Current perspectives on ranibizumab

References

• GrisantiSTatarOThe role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degenerationProg Retin Eye Res200827437239018621565
   PubMed Web of Science ®Google Scholar
• KvantaAAlgverePVBerglinLSeregardSSubfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factorInvest Ophthalmol Vis Sci1996379192919348759365
   PubMed Web of Science ®Google Scholar
• AdamisAPAielloLPD’AmatoRAAngiogenesis and ophthalmic diseaseAngiogenesis19993191414517440
   PubMedGoogle Scholar
• AdamisAPShimaDTThe role of vascular endothelial growth factor in ocular health and diseaseRetina200525211111815689799
   PubMed Web of Science ®Google Scholar
• SeddonJMChenCAThe epidemiology of age-related macular degenerationInt Ophthalmol Clin2004444173915577562
   PubMedGoogle Scholar
• BresslerNMAge-related macular degeneration is the leading cause of blindnessJAMA2004291151900190115108691
   PubMedGoogle Scholar
• SaeedMUGkaragkaniEAliKEmerging roles for antiangiogenesis factors in management of ocular diseaseClin Ophthalmol2013653354323515639
   PubMedGoogle Scholar
• VerittiDSaraoVLanzettaPNeovascular age-related macular degenerationOphthalmologica2012227Suppl 1112022517121
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTANCHOR Study GroupRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology200911615765.e519118696
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• AbrahamPYueHWilsonLRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2Am J Ophthalmol20101503315324.e120598667
   PubMed Web of Science ®Google Scholar
• SingerMAAwhCCSaddaSHORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degenerationOphthalmology201211961175118322306121
   PubMed Web of Science ®Google Scholar
• BoyerDSHeierJSBrownDMFrancomSFIanchulevTRubioRGA Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degenerationOphthalmology200911691731173919643495
   PubMed Web of Science ®Google Scholar
• BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology201312051046105623352196
   PubMed Web of Science ®Google Scholar
• HoACBusbeeBGRegilloCDHARBOR Study GroupTwenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology2014121112181219225015215
   PubMed Web of Science ®Google Scholar
• CampochiaroPAHeierJSFeinerLBRAVO InvestigatorsRanibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology2010117611021112.e120398941
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPABhisitkulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III studyOphthalmology201111881594160221684606
   PubMed Web of Science ®Google Scholar
• VarmaRBresslerNMSuñerIBRAVO and CRUISE Study GroupsImproved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trialsOphthalmology2012119102108211822817833
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPASinghRPCRUISE InvestigatorsRanibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology2010117611241133.e120381871
   PubMed Web of Science ®Google Scholar
• HeierJSCampochiaroPAYauLRanibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trialOphthalmology2012119480280922301066
   PubMed Web of Science ®Google Scholar
• CampochiaroPABrownDMAwhCCSustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III studyOphthalmology2011118102041204921715011
   PubMed Web of Science ®Google Scholar
• CampochiaroPASophieRPearlmanJRETAIN Study GroupLong-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN studyOphthalmology2014121120921924112944
   PubMed Web of Science ®Google Scholar
• NguyenQDBrownDMMarcusDMRISE RIDE Research GroupRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology2012119478980122330964
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJCATT Research GroupRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGFineSLComparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M reportOphthalmology199510210142514339097788
   PubMed Web of Science ®Google Scholar
• BrownDMNguyenQDMarcusDMRIDE RISE Research GroupLong-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDEOphthalmology2013120102013202223706949
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthURESTORE study groupThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology2011118461562521459215
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthULangGEHolzFGRESTORE Extension Study GroupThree-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension studyOphthalmology201412151045105324491642
   PubMed Web of Science ®Google Scholar
• ElmanMJAielloLPBeckRWDiabetic Retinopathy Clinical Research NetworkRandomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edemaOphthalmology2010117610641077.e3520427088
   PubMed Web of Science ®Google Scholar
• ElmanMJAyalaABresslerNMDiabeticRetinopathyClinical Research NetworkIntravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial resultsOphthalmology Epub20141028
   Google Scholar
• GrunwaldJEDanielEHuangJCATT Research GroupRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trialsOphthalmology2014121115016124084496
   PubMed Web of Science ®Google Scholar
• GrunwaldJEPistilliMYingGGrowth of geographic atrophy in the comparison of age-related macular degeneration treatments trialsOphthalmology Epub20141224
   Web of Science ®Google Scholar
• DankinHAWordsworthSRogersCAIVAN Study InvestigatorsCost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trialBMJ Open201447e005094
   Web of Science ®Google Scholar
• SteinJDNewman-CaseyPAMrinaliniTLeePPHuttonDWCost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degenerationOphthalmology2014121493694524405740
   PubMed Web of Science ®Google Scholar
• Argon laser photocoagulation for macular edema in branch retinal vein occlusion. The Branch Vein Occlusion Study GroupAm J Ophthalmol19849832712826383055
   PubMed Web of Science ®Google Scholar
• HiraiFEKnudtsonMDKleinBEKleinRClinically significant macular edema and survival in type 1 and type 2 diabetesAm J Ophthalmol2008145470070618226797
   PubMed Web of Science ®Google Scholar